Progenics Pharmaceuticals has initiated a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a novel compound designed to deliver a cell-killing drug to the patient's prostate cancer cells by targeting a of prostate cancer that is expressed on the surface of those cells. PSMA ADC consists of antibody-drug conjugates designed to be absorbed by the cell and release active anti-cancer drug, thereby destroying the malignant cell.
The study will evaluate responses in the validated biomarker and circulating tumor cells bone.
“This type of cancer therapy is unique and we believe that PSMA ADC is the most advanced clinical-stage candidate antibody-drug conjugate in development to treat prostate cancer.” said Robert J. Israel, M.D., Progenics’ Senior Vice President, Medical Affairs & Clinical Research.
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company dedicated to developing innovative medicines to treat disease, with a focus on cancer and related conditions. Progenics’ pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
ADC's has received much attention in the biologic R&D space for their targeted capabilities. Sanjay Patel of Takeda will be presenting Takeda's work on cell-engineering strategies for novel antibody drug conjugates at the Cell Culture World Congress USA event taking place in Washington D.C. in November.
To read the original article click here
To learn more about the Cell Culture World Congress USA event click here